HMOX1 and kidney disorder: The potential use of pharmacological HO inducers in renal medicine is underscored by the extent to which the HO system inhibits inflammatory tissue damage via a number of pathways, including the capacity of renal HO to suppress the transcription of NF-κB, activating protein-1 and c-Jun-N-terminal kinase (JNK), which are strongly proinflammatory transcription factors contributing significantly to renal disease [89].